Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05102214 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.

NCT NCT05102214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05102214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Shanghai Henlius Biotech
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 3, 2022
Completion date
February 29, 2024
Enrollment
150 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors, non-small cell lung cancer